December 2017 ARTICLE LIST >>
PharmaTutor (December - 2017)
ISSN: 2347 - 7881
(Volume 5, Issue 12)
Received On: 13/08/2017; Accepted On: 13/09/2017; Published On: 01/12/2017
AUTHORS:
K.Gopalasatheeskumar1*, S.Komala2 and M.Mahalakshmi2
1KMCH college of Pharmacy,
Coimbatore, Tamil Nadu, India.
2Jaya College of Paramedical sciences,
College of Pharmacy, Thiruninravur,
Chennai, Tamil Nadu, India.
*gskpungai@gmail.com
ABSTRACT:
The review was carried out to discuss in detail about the polymeric nanoparticles for diabetic treatment. The diabetes is the chronic metabolic disorder characterized by the deficiency of insulin production. The various treatments are available for the diabetes and the nanoparticles are having the several advantages. The various types of nanoparticles are available for the anti-diabetic drugs; the polymeric nanoparticles are the one of the most commonly used nanoparticles. The polymeric nanoparticles are commonly 10-1000nm in size. The polymeric nanoparticles are formulated by drug with the polymers. The main advantages of the polymeric nanoparticles are the simplest preparation method, targeted delivery, the minimizing of the dose and high therapeutic efficiency. In this review was mainly can be focused on advantages, disadvantages of polymeric nanoparticles, various polymers, various formulation techniques, diabetes disease profile, insulin production, various anti-diabetic drugs and the polymeric nanoparticle formulation of anti-diabetic drugs.
How to cite this article: Gopalasatheeskumar K, Komala S, Mahalakshmi M;An Overview on Polymeric Nanoparticles used in the treatment of Diabetes Mellitus; PharmaTutor; 2017; 5(12);40-46
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Amolkumar Lokhande, Satyendra Mishra, Ravindra Kulkarni and Jitendra Naik (2013); Formulation and Evaluation of Glipizide Loaded Nanoparticles; Int J Pharm Pharm Sci; Vol. 5 No. 4; 147-151.
2. Anusha R., Somasundaram I., Ravichandiran V., Kausalya J., Joseprakash D and Senthilnathan B. (2011); Effect of Cholesterol and Surfactant Concentration on Solid Lipid Nanosuspension of Ropinirole Hydrochloride; Journal of Pharmacy Research; Vol. 4 No. 6; 1606-1609.
3. Deopa Deepika, Sharma Kumar Satish and Singh Lalit. (2013); Current updates on Anti-Diabetic Therapy; JDDT; Vol. 3 No. 6; 121-126.
4. Ebtiha F. Alamoudi, Wagdy K.B Khalil, Inas S. Ghaly, Nagwa H.A Hassan and Ekram S. Ahmed. (2014); Nanoparticles from of Costus speciosus extract Improves the Antidiabetic and AntilipidemicEffects Against STZ-induced Diabetes Mellitus in Albino Rats; Int. J. Pharm. Sci. Rev. Res.; Vol. 29 No. 1; 279-288.
5. Fowler M. J. (2008); Microvascular and macrovascular complication of diabetes; Clinical diabetes; Vol. 26 No. 2; 77-82.
6. Harris M.I., Flegal K.M., Cowie C.C., Eberhardt M.S., Goldstein D.E., Little R.R., Wiedmeyer H.M. and Byrd Holt D.D.(1998); Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey 1988–1994; Diabetes Care; Vol. 21; 518–524.
7. Konwar Ranjit and Ahmed Abdul Baquee.(2013); Nanoparticle: A review of preparation, characterization and application; IRJP; Vol. 4 No.4;48-52.
8. Lokhande A.K., Sathyendra and Kulkarni R.(2013); Formulation and evaluation of Glipizide loaded nanoparticles; Int J Pharm Pharm Sci; Vol. 5 No.4; 147-151.
9. Mohanraj V.J. and Chen Y.(2006); Nanoparticles – a review; Tropical journal of pharmaceutical research; Vol. 5 No.1; 561-573.
10. Mounica Reddy M., Shanmugam V. and Rajesh Kaza.(2012); Design and characterization of Insulin Nanoparticles for oral delivery; IJIPSR; Vol. 3 No. 3; 238-243.
11. Nagarajan E., Shanmugasundaram P., Ravichandiran V., Vijayalakshmi A., Senthilnathan B. and Masilamani K.(2015); Development and Evaluation of Chitosan Based Polymeric Nanoparticles of an Antiulcer Drug Lansoprazole; JAPS; Vol. 5 No. 4; 20-25.
12. Nagavarma B.V.N., Hemant K.S. Yadav, Ayaz A., Vasudha S. and Shivakumar H.G.(2012); Different techniques for preparation of polymeric nanoparticles- A review; Asian J Pharm Clin Res.; Vol. 5 No.3; 16-23.
13. Neha Yadav, Sunil Khatak and Udai Vir Singh S.A.(2013); Solid lipid nanoparticles- A review; Int J App Pharm; Vol. 5 No.2; 8-18.
14. Naik J.B. and Mokale V.J.(2012); Formulation and evaluation of Repaglimide nanoparticles as sustained release carriers; International Journal of Pharmaceutical Sciences; Vol. 1 No. 5; 259-266.
15. Nishikant C. Shinde, Nisha J. Keskar and Prashant D. Argade.(2012); Nanoparticles: Advances in Drug Delivery systems; RJPBCS; Vol. 3 No. 1; 922-929.
16. Pijush Kumar Paul, AlongkotTreetong and Roongnapa Suedee.(2017); Biomimetic insulin-imprinted polymer nanoparticles as a potential oral drug delivery system; Acta Pharm; Vol. 67; 149–168.
17. Pratap C. Naha, Hugh J. Byrne and Amulya K. Panda.(2012); Role of polymeric excipients on controlled release profile of Glipizide from PLGA and Eudragit RS 100 Nanoparticles; JND; Vol. 1; 1–9.
18. Priyanka Saharan, Bhatt D.C., Saharan S.P. and Kavita Bahmani.(2015); Preparation and characterization of antidiabetic drug loaded polymeric nanoparticles; Der Pharma Chemical; Vol. 7 No. 12; 398-404.
19. Sanjukta Duarah, Kunal Pujari, Jyotirmoy Ghosh, Dhanalekshmi and Unnikrishnan.(2015); Formulation and Evaluation of Metformin Engineered Polymeric Nanoparticles for Biomedical Purpose; RJPBCS;Vol. 6 No. 3; 1005-1019.
20. Senthilnathan B., Ameerkhan H, Aswini Sofia P.I., Abirami M., Bharath T., Ajithkumar T. and Maheswaran A.(2015); Review on various approaches on Preparation, Characterization and Applications of Polymeric Nanoparticles; WJPR; Vol. 4 No.6; 645-663.
21. Senthilnathan B., Maheswaran A., Gopalasatheeskumar K., Masilamani K. and Raihana Z. Edros.(2016); Formulation and Evaluation of Pregabalin Loaded Eudragit S100 Nanoparticles; IJETS; Vol. 6 No.1; 64-70.
22. Sovan Lal Pal, Utpal Jana, Manna P.K., Mohanta G.P. and Manavalan R.(2011); Nanoparticle: An overview of preparation and characterization; JAPS; Vol. 1 No.06; 228-234.
23. Umar Faruksha A. and Vetrichelvan T.(2013); Formulation, Characterization and Optimization of Pioglitazone Hydrochloride Nanoparticles by Solvent Displacement Method Using 32 Factorial design; Int J PharmTech Res; Vol. 5 No. 2; 754-766.
24. Yasemin Budama Kilinc, Rabia Cakir-Koc and Ozlem Horzum Bayir.(2017); The Cytotoxicity, Characteristics, and optimization of Insulin-loaded Nanoparticles; Orbital: Electron. J. Chem.; Vol. 9 No.1; 66-71.
25. Zhiyang Ke, Han Guo, Xi Zhu, Yun Jin and Yuan Huang.(2015); Efficient Peroral Delivery of Insulin via Vitamin B12 Modified Trimethyl Chitosan Nanoparticles; JPPS; Vol. 18 No. 2; 155 – 170.
.png)
